Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

King Intensifying CEO Search; Gregory To Immediately Step Down

This article was originally published in The Pink Sheet Daily

Executive Summary

Gregory had planned to retire as CEO once a successor was found. King is facing federal investigations into its Medicaid rebate accounting practices and recently issued an earnings warning.
Advertisement

Related Content

Newcomer Graceway Acquires 3M’s American Pharmaceutical Business
Newcomer Graceway Acquires 3M’s American Pharmaceutical Business
Mylan To Pay $4 Bil. For King Ahead Of Launch Of Beta Blocker Nebivolol
Mylan To Pay $4 Bil. For King Ahead Of Launch Of Beta Blocker Nebivolol
King Names Markison President & CEO
King Names Markison Acting CEO; President Macione Steps Down
CEO Gregory To Step Down, Search For Successor Underway
CEO Gregory To Step Down, Search For Successor Underway
King Wholesaler Agreements Planned To Stabilize Altace Inventory Levels
King Pharma Names Markison COO

Topics

Advertisement
UsernamePublicRestriction

Register

PS059428

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel